Nicotine could have a role in breast cancer development and metastasis, it has been found. The study has been published in Cancer Research, a journal of the American Association for Cancer Research. It was conducted by researchers at the Beth Israel Deaconess Medical Center, is among the first to explore the effects of nicotine on mammary cells.
"Although numerous studies indicate the role of nicotine exposure in tumor promotion, little is known about the effect of nicotine on breast tumor development, especially on the metastatic process of breast cancer," said lead author Chang Yan Chen, at Beth Israel Deaconess Medical Center.
Through a series of in vitro tests Chen and her team of researchers determined that breast epithelial-like MCF10A cells and cancerous MCF7 cells both express several subunits of nAChR (nicotine receptor), that when bound, initiate a signaling process, potentially increasing cell growth and migration.
"We were able to determine that mammary cells express different subunits of nAChR and that nicotine, possibly through perturbing cell cycle checkpoints, potentiates tumorigenesis in mammary cancer-prone or cancer cells," Chen said.
In vivo studies confirmed these findings. When injected into the tail of a mouse the cancerous MCF7 cells migrated to the lungs.
From in vivo and in vitro studies, it indicates that nicotine is not a conventional carcinogen, but rather it combines with other yet to be determined factors to enable tumorigenesis.
"In vitro and in vivo tests showed that no metastasis occurs when the administration of nicotine alone," said Chen. "At this point we can only suggest that nicotine potentiates the growth-related process."
Chen hopes to conduct more studies, in particular under the genetic backgrounds with loss or defect of different tumor suppressors, to further explore the effects of nicotine in relation to first- and second-hand exposure, on breast cancer initiation and development.
The American Association for Cancer Research, founded in 1907, is the world's oldest and largest professional organization dedicated to advancing cancer research.
The AACR Annual Meeting attracts more than 17,000 participants who share the latest discoveries and developments in the field.